Guy Adami: Alkermes a 'No-Play' at This Level
January 09, 2012 at 18:12 PM EST
Alkermes expects FDA approval for its new diabetes drug this month, but that might not be enough to make the stock worth buying, trader Guy Adami said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|